Panchratna Remedies India Limited
Pharmaceutical company incorporated in 1988, based in Dumral, Gujarat.
1988 | Kheda, Gujarat (India) | Active
Panchratna Remedies India Profile
Key Indicators
- Authorised Capital ₹ 1.20 Cr
- Paid Up Capital ₹ 8.05 M
- Company Age 36 Year, 6 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth 70.96%
- Profit Growth 119.38%
- Ebitda 98.19%
- Net Worth 1.19%
- Total Assets 0.93%
About Panchratna Remedies India
Panchratna Remedies India Limited (PRIL) is a Public Limited Indian Non-Government Company incorporated in India on 12 August 1988 and has a history of 36 years and six months. Its registered office is in Kheda, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.20 Cr and a paid-up capital of Rs 8.05 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjaybhai Patel, Hiteshkumar Patel, and Binaben Patel serve as directors at the Company.
Company Details
- Location
Kheda, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231GJ1988PLC011109
- Company No.
011109
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Aug 1988
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Pharma
Who are the key members and board of directors at Panchratna Remedies India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjaybhai Patel  | Director | 05-Jul-1995 | Current |
| Hiteshkumar Patel | Additional Director | 16-May-2006 | Current |
| Binaben Patel | Director | 22-Nov-2006 | Current |
Financial Performance of Panchratna Remedies India.
Panchratna Remedies India Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 70.96% increase. The company also saw a substantial improvement in profitability, with a 119.38% increase in profit. The company's net worth moved up by a moderate rise of 1.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Panchratna Remedies India?
In 2021, Panchratna Remedies India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Envee Drugs Private LimitedSanjaybhai Patel is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Panchratna Remedies India?
Unlock and access historical data on people associated with Panchratna Remedies India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Panchratna Remedies India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Panchratna Remedies India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.